Imbruvica
/
Imbruvica (ibrutinib) is a Bruton's tyrosine kinase inhibitor indicated for the treatment of certain types of blood cancers, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). It is administered as an oral tablet and is available by prescription only. Patients are advised to monitor for signs of bleeding, as Imbruvica may increase the risk of bleeding events, and it should not be used in patients with a history of certain heart conditions, such as atrial fibrillation, without careful consideration.
FAQs about Imbruvica
What should I do if I miss a dose?
If you miss a dose of Imbruvica, take it as soon as you remember on the same day. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed dose. This information is found in the Patient Counseling Information section of the label.
Can I take Imbruvica while pregnant or breastfeeding?
Imbruvica may cause harm to an unborn baby, and it is not recommended for use during pregnancy. Women who are pregnant or planning to become pregnant should discuss the risks with their healthcare provider. It is also advised that breastfeeding should be avoided while taking Imbruvica, as it is not known if the drug passes into breast milk. This information is detailed in the Warnings and Precautions section of the label.
Can I stop taking Imbruvica suddenly?
Patients are advised not to stop taking Imbruvica without consulting their healthcare provider. Abrupt discontinuation may lead to a worsening of the condition being treated. This caution is mentioned in the Warnings and Precautions section of the label.
How should I store Imbruvica?
Imbruvica should be stored at room temperature, away from moisture and heat. It is important to keep the medication out of reach of children. This storage information is provided in the Storage and Handling section of the label.
25
commonly-prescribed
medication.